Halia Therapeutics CEO to Speak at Med Investment Forum 2025 in Abu Dhabi

Halia Therapeutics CEO to Speak at Med Investment Forum 2025

Halia Therapeutics, a pioneering biopharmaceutical company focused on therapies that target the innate immune system, has announced that its CEO, Dr. David Bearss, will be the keynote speaker at the upcoming Med Investment Forum 2025. This highly anticipated event is scheduled to take place on May 29, 2025, at the Rotana Beach Hotel in Abu Dhabi, UAE.

Exploring Genetic Resilience in Medicine

Dr. Bearss will deliver a compelling presentation titled "Pioneering a New Era of Medicine by Unlocking the Body's Power of Genetic Resilience." His keynote is expected to shed light on the insights gained from resilient individuals—those who remain free from disease despite their genetic predispositions. This examination of genetic resilience could revolutionize therapeutic development by providing new avenues for treatment.

"The key to solving medicine's toughest challenges lies in understanding why certain individuals are protected from disease," Dr. Bearss stated. "At Halia, we're leveraging that understanding to create therapies that reprogram the body's immune response on a molecular level, ushering in a new era of precision immunology."

Halia's Innovative Therapeutic Approach

Halia Therapeutics is at the forefront of redefining how inflammation mediates various medical conditions. The company has established a robust development pipeline, with notable programs including HT-6184, an NEK7 allosteric modulator currently in clinical trials for conditions such as myelodysplastic syndromes (MDS) and obesity. Another key program, HT-4253, seeks to replicate the protective genetic effects observed in APOE4 homozygotes, individuals who display resilience to Alzheimer's disease.

Halia's innovative approach is made possible by its commitment to utilizing population-scale genomic data to inform its research and development strategies. This focus is fundamental to the company's mission of creating breakthrough treatments for a range of inflammatory and neurodegenerative diseases.

A Premier Global Gathering

The Med Investment Forum, organized under the patronage of the UAE Ministry of Health and Prevention and in collaboration with the World Health Organization (WHO), is a prominent global platform that connects health ministers, investors, biotech leaders, and healthtech innovators. Halia's participation as a keynote speaker highlights both the company's commitment to innovation and the global impact that the Forum aims to facilitate.

The event serves as a critical opportunity for attendees to explore transformative biotech solutions and engage with key players influencing the future of healthcare.

Event Details

- Date: May 29, 2025
- Location: Rotana Beach Hotel, Abu Dhabi, UAE
- Website: Med Investment Forum

About Halia Therapeutics

Halia Therapeutics focuses on developing innovative therapies that modulate the innate immune system to treat diseases driven by inflammation. By investigating the biology underlying genetic resilience, Halia aims to craft groundbreaking treatments for a variety of conditions, including neurodegenerative disorders and metabolic diseases. For more information, visit Halia's website.

For media inquiries, please contact:
Taylor Avei
Director of Business Development
Halia Therapeutics
Email: [email protected]